These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND PR, PGR, progesterone receptor
1158 results:

  • 1. Prognostic implications of immunohistochemistry in patients with endometrial cancer.
    Anca-Stanciu MB; Manu A; Olinca MV; Coroleucă BC; Comandaşu DE; Coroleucă CA; Maier C; Brătilă E
    Rom J Morphol Embryol; 2024; 65(2):185-193. PubMed ID: 39020532
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Analysis of tumor microenvironment alterations in partially responsive rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Chen H; Zhang JH; Hao Q; Wu XL; Guo JX; Huang CX; Zhang J; Xing GS; An ZL; Ling Y; Zhao JG; Bao YN
    Int J Colorectal Dis; 2024 Jun; 39(1):99. PubMed ID: 38926205
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Multilevel analysis of social determinants of advanced stage colorectal cancer diagnosis.
    Dantas AAG; de Oliveira NPD; Costa GAB; Martins LFL; Dos Santos JEM; Migowski A; de Camargo Cancela M; de Souza DLB
    Sci Rep; 2024 Apr; 14(1):9667. PubMed ID: 38671078
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Exploring treatment outcomes in Stage II-III rectal cancer patients undergoing neoadjuvant therapy at a tertiary care center in Pakistan: a comprehensive analysis of pathological outcomes.
    Soomro MY; Khan SR; Muhammad H; Ahmad S; Zehra N; Ali I; Samar MR; Hameed A; Moosajee M; Rashid YA
    BMC Cancer; 2024 Apr; 24(1):479. PubMed ID: 38627736
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.
    Ding XH; Xiao Y; Chen F; Liu CL; Fu T; Shao ZM; Jiang YZ
    Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38602320
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Long-Term Outcomes of Self-Expandable Metallic Stents as a Bridge to Surgery for Obstructive and Symptomatic Primary Tumors of Stage IV colorectal cancer: A Propensity-Score Analysis.
    Sekioka A; Ota S; Ito T; Mizukami Y; Tsuboi K; Okamura M; Lee Y; Ishida S; Shim Y; Adachi Y
    J Laparoendosc Adv Surg Tech A; 2024 Jul; 34(7):561-567. PubMed ID: 38574310
    [No Abstract]    [Full Text] [Related]  

  • 8. Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.
    Feng H; Zhang S; Zhou Q; Han F; Du G; Wang L; Yang X; Zhang X; Yu W; Wei F; Hao X; Ren X; Zhao H
    Front Immunol; 2024; 15():1302903. PubMed ID: 38500886
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Type 2 diabetes mellitus and post-colonoscopy colorectal cancer: clinical and molecular characteristics and survival.
    Boysen ML; Troelsen FS; Sørensen HT; Erichsen R
    Cancer Causes Control; 2024 Jul; 35(7):1043-1052. PubMed ID: 38483686
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
    Corcoran RB; Do KT; Kim JE; Cleary JM; Parikh AR; Yeku OO; Xiong N; Weekes CD; Veneris J; Ahronian LG; Mauri G; Tian J; Norden BL; Michel AG; Van Seventer EE; Siravegna G; Camphausen K; Chi G; Fetter IJ; Brugge JS; Chen H; Takebe N; Penson RT; Juric D; Flaherty KT; Sullivan RJ; Clark JW; Heist RS; Matulonis UA; Liu JF; Shapiro GI
    Clin Cancer Res; 2024 May; 30(9):1739-1749. PubMed ID: 38456660
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
    Yan H; Song L; Li Y; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Huang Z; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zhang Y; Zeng L
    Cancer Immunol Immunother; 2024 Mar; 73(4):74. PubMed ID: 38451314
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Value of diffusion kurtosis MR imaging and conventional diffusion weighed imaging for evaluating response to first-line chemotherapy in unresectable pancreatic cancer.
    Zhang Z; Zhang Y; Hu F; Xie T; Liu W; Xiang H; Li X; Chen L; Zhou Z
    Cancer Imaging; 2024 Feb; 24(1):29. PubMed ID: 38409049
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
    Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
    Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report.
    Kikuchi K; Ogawa M; Sasaki A
    J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Rare germline mutation and MSH2-&MSH6 + expression in a double primary carcinoma of colorectal carcinoma and endometrial carcinoma: a case report.
    Zhang T; Huang X; Liu W; Ling X; Su Z; Huang M; Che S
    Diagn Pathol; 2024 Jan; 19(1):25. PubMed ID: 38297350
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Comparison of phenomic profiles in the All of Us Research Program against the US general population and the UK Biobank.
    Zeng C; Schlueter DJ; Tran TC; Babbar A; Cassini T; Bastarache LA; Denny JC
    J Am Med Inform Assoc; 2024 Apr; 31(4):846-854. PubMed ID: 38263490
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The enigma of incisional hernia prediction unraveled: external validation of a prognostic model in colorectal cancer patients.
    Amro C; Smith L; Shulkin J; McGraw JR; Hill N; Broach RB; Torkington J; Fischer JP
    Hernia; 2024 Apr; 28(2):547-553. PubMed ID: 38227093
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Validity assessment of the POLARS score tool in the prediction of post rectal cancer surgery LARS score in a population-based Swedish cohort.
    Rethy B; Nordenvall C; Pieniowski E; Jansson-Palmer G; Johar A; Lagergren P; Abraham-Nordling M
    BMJ Open Gastroenterol; 2024 Jan; 11(1):. PubMed ID: 38199776
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases.
    Peng K; Li Y; Su H; Lan C; Huang Z; Wei Y; Liao X; Peng M; Peng T; Zhu G
    Front Immunol; 2023; 14():1325445. PubMed ID: 38173715
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 58.